Trial Profile
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-Cd7 CAR-NK cells (Primary)
- Indications Acute myeloid leukaemia; Extranodal NK-T-cell lymphoma; Large granular lymphocytic leukaemia; Leukaemia; Lymphoma; Peripheral T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 28 Apr 2016 New trial record